AVLSA
DYN icon

Atlas Venture Life Science Advisors’s Dyne Therapeutics DYN Stock Holding History

Atlas Venture Life Science Advisors’s Portfolio DYN Stock Details DYN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$151M Sell
6,800,099
-2,330,366
-26% -$43.3M 17.14% 2
2026
Q1 		$166M Hold
9,130,465
– – 20.95% 2
2025
Q4 		$179M Hold
9,130,465
– – 20.64% 2
2025
Q3 		$116M Hold
9,130,465
– – 15.35% 3
2025
Q2 		$86.9M Hold
9,130,465
– – 13.12% 3
2025
Q1 		$95.5M Buy
9,130,465
+1,111,111
+14% +$15.9M 18.3% 3
2024
Q4 		$189M Sell
8,019,354
-782
-0% -$23.1K 23.05% 2
2024
Q3 		$288M Hold
8,020,136
– – 26.71% 1
2024
Q2 		$283M Hold
8,020,136
– – 29.8% 1
2024
Q1 		$228M Sell
8,020,136
-1,865,313
-19% -$42.2M 21.01% 1
2023
Q4 		$131M Hold
9,885,449
– – 15.66% 3
2023
Q3 		$88.6M Hold
9,885,449
– – 13.72% 3
2023
Q2 		$111M Hold
9,885,449
– – 13.84% 3
2023
Q1 		$114M Buy
9,885,449
+15,966
+0.2% +$207K 15.42% 2
2022
Q4 		$114M Buy
9,869,483
+934,581
+10% +$10.8M 13.78% 3
2022
Q3 		$113M Hold
8,934,902
– – 12.52% 4
2022
Q2 		$61.4M Hold
8,934,902
– – 10.26% 3
2022
Q1 		$86.1M Hold
8,934,902
– – 10.89% 2
2021
Q4 		$106M Buy
+8,934,902
New +$126M 9.76% 3

Other funds holding DYN

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Atlas Venture Life Science Advisors's DYN Position: Q2 2026 in Review

Atlas Venture Life Science Advisors reduced its Dyne Therapeutics (DYN) stake by 26% in Q2 2026, selling an estimated $43.3M and leaving 6,800,099 shares worth $151M. The position accounts for 17.14% of the portfolio, ranked #2.

Atlas Venture Life Science Advisors first reported a position in DYN in Q4 2021 and has held it in 19 quarters since. The position peaked at $288M in Q3 2024. 246 funds tracked by Wall St. Rank hold DYN as of Q2 2026.

  • Atlas Venture Life Science Advisors held 6,800,099 shares of Dyne Therapeutics worth $151M as of Q2 2026.
  • Atlas Venture Life Science Advisors sold 2,330,366 Dyne Therapeutics shares in Q2 2026, an estimated $43.3M.
  • Dyne Therapeutics made up 17.14% of Atlas Venture Life Science Advisors's portfolio in Q2 2026, its #2 holding.
  • Atlas Venture Life Science Advisors first reported a position in Dyne Therapeutics in Q4 2021 and has held it in 19 quarters since.
  • Atlas Venture Life Science Advisors's Dyne Therapeutics position peaked at $288M in Q3 2024.
  • 246 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q2 2026.

Based on Atlas Venture Life Science Advisors's 13F filing for Q2 2026, filed 13 Aug 2026.